Background/Aims: Constitutional delay of growth and puberty (CDGP) with short stature is one of the most common problems in pediatrics. We compared the effects of letrozole with that of oxandrolone on predicted adult height (PAH), puberty, bone mineral density, serum insulin-like growth factor 1 (IGF-1) and blood lipoproteins. Methods: In a prospective, double-blind, randomized, placebo-controlled clinical trial, 91 CDGP boys (12.6–14.6 years old) with predicted short stature were treated with letrozole (2.5 mg/day), oxandrolone (2.5 mg/day), or placebo, at the outpatient pediatric endocrine clinic of Mofid Children’s Hospital in Tehran for 2 years. Results: Letrozole differed from oxandrolone and placebo in significantly increasing PAH (p < 0.05), and slightly but significantly decreasing HDL-cholesterol. Oxandrolone, and to a lesser degree letrozole, significantly increased the height standard deviation score and bone age compared to placebo. Conclusion: This first randomized controlled clinical trial in CDGD teenage boys with predicted short stature shows that letrozole increases PAH more than oxandrolone and advances pubertal stage and bone mineralization less.

1.
Rosenfield RL: Diagnosis and management of delayed puberty. J Clin Endocrinol Metab 1990;70:559–562.
2.
Ambler GR: Androgen therapy for delayed male puberty. Curr Opin Endocrinol Diabetes Obes 2009;16:232–239.
3.
Richmond EJ, Rogol AD: Male pubertal development and the role of androgen therapy. Nat Clin Pract Endocrinol Metab 2007;3:338–344.
4.
Lampit M, Hochberg Z: Androgen therapy in constitutional delay of growth. Horm Res 2003;59:270–275.
5.
Papadimitriou A, Wacharasindhu S, Pearl K, Preece MA, Stanhope R: Treatment of constitutional growth delay in prepubertal boys with a prolonged course of low-dose oxandrolone. Arch Dis Child 1991;66:841–843.
6.
Wilson DM, McCauley E, Brown DR, Dudley R: Oxandrolone therapy in constitutionally delayed growth and puberty. Bio-Technology General Corporation Cooperative Study Group. Pediatrics 1995;96:1095–1100.
7.
Zadik Z, Sinai T, Zung A, Reifen R: Vitamin A and iron supplementation is as efficient as hormonal therapy in constitutionally delayed children. Clin Endocrinol (Oxf) 2004;60:682–687.
8.
Hero M, Wickman S, Dunkel L: Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty. Clin Endocrinol (Oxf) 2006;64:510–513.
9.
Dunkel L: Update on the role of aromatase inhibitors in growth disorders. Horm Res 2009;1:57–63.
10.
Wickman S, Sipila I, Ankarberg-Lidgren C, NorjavaaraE, Dunkel L: A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet 2001;357:1743–1748.
11.
Hero M, Norjavaara E, Dunkel L: Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. J Clin Endocrinol Metab 2005;90:6396–6402.
12.
Dunkel L, Wickman S: Treatment of delayed male puberty: efficacy of aromatase inhibition. J Pediatr Endocrinol Metab 2001;14:1541–1546.
13.
Grumbach MM: Estrogen, bone, growth and sex: a sea change in conventional wisdom. J Pediatr Endocrinol Metab 2000;13:1439–1455.
14.
Cernich J, Jacobson JD, Moore WV, Popovic J: Use of aromatase inhibitors in children with short stature. Pediatr Endocrinol Rev 2004;2:2–7.
15.
Shulman DI, Francis GL, Palmert MR, Eugster EA; Lawson Wilkins Pediatric Endocrine Society Drug and Therapeutics Committee: Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development. Pediatrics 2008;121:975–983.
16.
Traggiai C, Stanhope R: Disorders of pubertal development. Best Pract Res Clin Obstet Gynaecol 2003;17:41–56.
17.
Semiz S, Kurt F, Kurt DT, Zencir M, Sevinç O: Pubertal development of Turkish children. J Pediatr Endocrinol Metab 2008;21:951–961.
18.
Prader A: Testicular size: assessment and clinical importance. Triangle 1966;7:240–243.
19.
Tanner J: Growth at Adolescence, ed 2. Oxford, Blackwell, 1962.
20.
Sobradillo B, Zachmann M, Frank M, Frisch H, Prader A: Bayley-Pinneau, Roche and Tanner height predictions in various conditions. Pediatr Res 1978;12:151.
21.
Bayley N, Pinneau SR: Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr 1952;40:423–441.
22.
Sperlich M, Butenandt O, Schwarz PH: Final height and predicted height in boys with untreated constitutional growth delay. Eur J Pediatr 1995;154:627–632.
23.
Greulich WW, Pyle Si: Radiographic Atlas of Skeletal Development of Hand and Wrist, ed 2. Stanford, Stanford University Press, 1959.
24.
Wang J, Thornton JC, Horlick M, Formica C, Wang W, Pierson RN Jr: Dual X-ray absorptiometry in pediatric studies: changing scan modes alters bone and body composition measurements. J Clin Densitom 1999;2:135–141.
25.
Yilmaz D, Ersoy B, Bilgin E, Gümüşer G, Onur E, Pinar ED: Bone mineral density in girls and boys at different pubertal stages: relation with gonadal steroids, bone formation markers, and growth parameters. J Bone Miner Metab 2005;23:476–482.
26.
Carter DR, Bouxsein ML, Marcus R: New approaches for interpreting projected bone densitometry data. J Bone Miner Res 1992;7:137–145.
27.
Lu PW, Cowell CT, Lloyd-Jones SA, Briody JN, Howman-Giles R: Volumetric bone mineral density in normal subjects, aged 5–27 years. J Clin Endocrinol Metab 1996;81:1586–1590.
28.
Kalkwarf HJ, Zemel BS, Gilsanz V, Lappe JM, Horlick M, Oberfield S, Mahboubi S, Fan B, Frederick MM, Winer K, Shepherd JA: Whole-body bone mineral content in healthy children and adolescents. J Clin Endocrinol Metab 2007;92:2087–2099.
29.
Ward KA, Ashby RL, Roberts SA, Adams JE, Zulf Mughal M: UK reference data for the Hologic QDR Discovery dual-energy X-ray absorptiometry scanner in healthy children and young adults aged 6–17 years. Arch Dis Child 2007;92:53–59.
30.
Molgaard C, Thomsen BL, Prentice A, Cole TJ, Michaelsen KF: Whole-body bone mineral content in healthy children and adolescents. Arch Dis Child 1997;76:9–15.
31.
Apter D, Jánne O, Karvonen P, Vihko R: Simultaneous determination of five sex hormones in human serum by radioimmunoassay after chromatography on Lipidex-5000. Clin Chem 1976;22:32–38.
32.
Brugts MP, Ranke MB, Hofland LJ, van der Wansem K, Weber K, Frystyk J, Lamberts SW, Janssen JA: Normal values of circulating insulin-like growth factor-I bioactivity in the healthy population: comparison with five widely used IGF-I immunoassays. J Clin Endocrinol Metab 2008;93:2539–2545.
33.
Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.
34.
Keenan BS, Richards GE, Ponder SW, Dallas JS, Nagamani M, Smith ER: Androgen-stimulated pubertal growth: the effects of testosterone and dihydrotestosterone on growth hormone and insulin-like growth factor-I in the treatment of short stature and delayed puberty. J Clin Endocrinol Metab 1993;76:996–1001.
35.
Van der Eerden BCJ, Van Til NP, Brinkmann AO, Lowik CWGM, Wit JM, Karperian M: Sex differences in the expression of the androgen receptor in the tibial growth plate and metaphyseal bone of the rat. Bone 2002;30:891–896.
36.
Eshet R, Maor G, Ben Ari T, Ben Eliezer M, Gat-Yablonski G, Philip M: The aromatase inhibitor letrozole increases epiphyseal growth plate height and tibial length in prepubertal male mice. J Endocrinol 2004;182:165–172.
37.
Wickman S, Kajantie E, Dunkel L: Effects of suppression of estrogen action by the P450 aromatase inhibitor letrozole on bone mineral density and bone turnover in pubertal boys. J Clin Endocrinol Metab 2003;88:3785–3793.
38.
Hero M, Mäkitie O, Kröger H, Nousiainen E, Toiviainen-Salo S, Dunkel L: Impact of aromatase inhibitor therapy on bone turnover, cortical bone growth and vertebral morphology in pre- and peripubertal boys with idiopathic short stature. Horm Res 2009;71:290–297.
39.
Zadik Z, Sinai T, Borondukov E, Zung A, Yaniv I, Reifen R: Longitudinal monitoring of bone accretion measured by quantitative multi-site ultrasound (QUS) of bones in patients with delayed puberty (a pilot study). Osteoporos Int 2005;16:1036–1041.
40.
Morrison JA, Sprecher DL, Biro FM, Apperson-Hansen C, Lucky AW, DiPaola LM: Estradiol and testosterone effects on lipids in black and white boys aged 10 to 15 years. Metabolism 2000;49:1124–1129.
41.
Kirkland RT, Keenan BS, Probstfield JL, Patsch W, Lin TL, Clayton GW, Insull W Jr: Decrease in plasma high-density lipoprotein cholesterol levels at puberty in boys with delayed adolescence. Correlation with plasma testosterone levels. JAMA 1987;257:502–507.
42.
Arslanian S, Suprasongsin C: Testosterone treatment in adolescents with delayed puberty: changes in body composition, protein, fat, and glucose metabolism. J Clin Endocrinol Metab 1997;82:3213–3220.
43.
Querfeld U, Dopper S, Gradehand A, Kiencke P, Wahn F, Zeisel HJ: Long-term treatment with growth hormone has no persisting effect on lipoprotein(a) in patients with Turner’s syndrome. J Clin Endocrinol Metab 1999;84:967–970.
44.
Halstead LS, Groah SL, Libin A, Hamm LF, Priestly L: The effects of an anabolic agent on body composition and pulmonary function in tetraplegia: a pilot study. Spinal Cord 2010;48:55–59.
45.
Malmendier CL, van den Bergen CJ, Emplit G, Delcroix C: A long-term study of the efficacy of oxandrolone in hyperlipoproteinemias. J Clin Pharmacol 1978;18:42–53.
46.
Hazzard WR, Wahl PW, Gagne C, Applebaum-Bowden D, Warnick GR, Albers JJ: Plasma and lipoprotein lipid responses to four hypolipid drugs. Lipids 1984;19:73–78.
47.
Wickman S, Saukkonen T, Dunkel L: The role of sex steroids in the regulation of insulin sensitivity and serum lipid concentrations during male puberty: a prospective study with a P450-aromatase inhibitor. Eur J Endocrinol 2002;146:339–346.
48.
Kennedy MC: Anabolic steroid abuse and toxicity. Aust NZ J Med 1992;22:374–381.
49.
Albrecht ED, Lane MV, Marshall GR, Merchenthaler I, Simorangkir DR, Pohl CR, Plant TM, Pepe GJ: Estrogen promotes germ cell and seminiferous tubule development in the baboon fetal testis. Biol Reprod 2009;81:406–414.
50.
McCarthy MJ, At-Taras EE, Pearl CA, Nitta-Oda BS, Roser JF, Conley AJ, Berger T: Suppression of endogenous estrogen during development affects porcine epididymal sperm maturation. Mol Reprod Dev 2006;73:1122–1128.
51.
Carreau S, Bourguiba S, Lambard S, Galeraud-Denis I, Genissel C, Levallet J: Reproductive system: aromatase and estrogens. Mol Cell Endocrinol 2002;193:137–143.
52.
Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K: Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995;80:3689–3698.
53.
Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS: Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994;331:1056–1061.
54.
Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS, Simpson ER: Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 1997;337:91–95.
55.
Patry G, Jarvi K, Grober ED, Lo KC: Use of the aromatase inhibitor letrozole to treat male infertility. Fertil Steril 2009;92:829.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.